Background Postoperative nausea and vomiting (PONV) is common after general anaesthesia, and corticosteroids are used in many protocols for enhanced recovery after surgery (ERAS). However, surgical techniques are developing, and ERAS protocols need to be reevaluated from time to time. Patients and method In this study, we compared the effects of oral vs. parenteral corticosteroid administration on postoperative nausea. Elective Roux-y-gastric bypass (RYGB) patients were randomly assigned to either 8 mg betamethasone orally (n = 50) or parentally (n = 25) or as controls (n = 25), in a double-blind design. PONV risk factors were noted. All patients had the same anaesthetic technique. Data were collected at baseline, on arrival to the recovery room (RR) and at five more time points during the first 24 h. Nausea and tiredness were patient assessed using visual analogue scales; rescue drug consumption was recorded. Results Operation time was 30-40 min. Neither demographics nor risk factors for nausea differed between groups. Neither peak values for nor total amount of nausea differed between groups. The number of supplemental injections was the same for all groups. Comments In a setting of modern laparoscopic RYGB, the value of betamethasone in preventing PONV seems to be limited. ERAS protocols may need re-evaluation.
Background
The use of an enhanced recovery after surgery (ERAS) protocol is a cornerstone in modern high-volume surgery. Much attention has been given to the problem of postoperative nausea and vomiting (PONV), and the preoperative administration of a corticosteroid is often included in such protocols. Internationally, the corticosteroid drug most commonly used for PONV prevention is dexamethasone. 1, 2 In reports on the efficacy of corticosteroids in bariatric surgery, parenterally administered dexamethasone has been used in multimodal therapies. [3] [4] [5] In Scandinavia, betamethasone is often the drug used. 6, 7 In our previous ERAS protocol, the choice of betamethasone was based on a randomized study 8 where there was no difference between the two drugs in preventing PONV. There are no reports on the possible benefit of oral administration on PONV, and intravenous injections are more timeconsuming and costlier than oral premedication is. In comparison with surgery 10 years ago, anaesthetic techniques have been refined, operative times have been reduced, laparoscopic instruments and cameras have been improved and nursing skills in a high-volume unit have improved.
Aleris Obesity specializes in bariatric surgery, performing close to 2000 procedures per year. Our fast-track model includes a completely standardized operation, anaesthesia and postoperative care, with our ERAS protocol central in treatment. This has led to a mean hospital time of 1.08 days, with 96 % of patients being able to go home on the first postoperative day. 9 However, in the light of the continuing development of surgery, ERAS protocols need constant development, and the present study aimed to examine one aspect of premedication: Can oral premedication with corticosteroids be equally effective as parenteral administration in reducing patient-experienced discomfort after laparoscopic RYGB during the first postoperative 24 h, i.e. until discharge from hospital? Or could modern surgical techniques obviate the need for corticosteroids? Primary endpoint was nausea, pain and tiredness were secondary.
Patients and methods
All operations were performed at the Lund Universityaffiliated Aleris Obesity unit, Central Hospital, Kristianstad, Sweden. Sample size was based on results from a previous randomized pilot study of 50 patients where a slight difference between test subjects and controls in nausea rating was picked up at the 2 % level. 10 Consecutive non-diabetic patients were recruited after informed consent from the lists for elective laparoscopic RYGB at Aleris Obesity. Randomization was performed on the morning of operation using closed envelopes in blocks of six. One test group of patients (n = 50) received 8 mg betamethasone (Betapred®; Swedish Orphan Biovitrum, Stockholm) as tablets. Another group (positive controls, n = 25) received betamethasone as an intravenous injection; both treatments given approximately 1 h before induction of anaesthesia. Another group (negative controls; n = 25) was given no active corticosteroid substance. Patients in all three groups received both injection and tablets. Patient demographics are given in Table 1 . Patients, surgeons and nurses at the ward were blinded to group belonging.
Collected variables Information on risk factors for postoperative nausea were collected (smoking, history of motion sickness, previous PONV). Patients assessed their discomfort using 100-mm visual analogue scales (VAS; 0 = no discomfort; 100 mm = worst imaginable). 11 Baseline values were obtained 30-60 min before anaesthesia. Follow-up values were obtained on arrival to the recovery room and 2, 4 and 8 h later. Final assessment was the following morning at 6 a.m., i.e. approximately 16 h postoperatively.
Our ERAS protocol has been described previously 12, 13 and contains the following:
Routine medication before operation: All patients were routinely given 2 g acetaminophen p.o. (Alvedon®, GlaxoSmithKline) and 120 mg etoricoxib p.o. (Arcoxia®, MSD) preoperatively. Cefuroxime (Cefuroxim, Fresenius KABI, Sweden), 1.5 g, was given as antibiotic prophylaxis. Anaesthesia: Patients were operated between 8 a.m. and 2.00 p.m. All patients had identical anaesthetic technique, with propofol (Propofol®, Lipura, Sweden) and remifentanil (Ultiva®, GlaxoSmithKline, Sweden) in a target-controlled infusion, as previously described. 11 At the induction of anaesthesia were given the following: Atracurium 20 mg i.v. (Atracurium-hameln®, Algol Pharma, Kista, Sweden), ketobemidon 10 mg i.v., (Ketogan®, Pfizer) and clonidine 22.5 μg i.v. (Catapresan®, Boehringer Ingelheim, Ingelheim am Rhein, Germany). No anaesthesia gases were used; propofol infusion was maintained until 3 min before completion of surgery. Surgical procedure: A standard Roux-Y gastric bypass with a small, completely separated pouch, a 60-cm biliopancreatic limb and a 150-cm antecolic, antegastric alimentary limb was performed in all patients as previously described 14 using 18 mmHg intraabdominal pressure throughout the procedure. The mesenterial openings were closed. Routine and on-demand medication after operation: Patients spent 2 h in the recovery room (RR), where they usually received injections of 0.5-1 mg alfentanil (Rapifen®, Jansen Pharmaceuticals, Sollentuna, Sweden) and 0.5-1.0 mg droperidol (Dridol®, Prostrakan AB, Kista, Sweden). Patients were then transferred to the ward. There, they received 1 g acetaminophen p.o. (Alvedon®, GlaxoSmithKline) every 6 h, and (Table 1 ). In addition, all patients started prophylaxis against deep venous thrombosis with the first injection 6-8 h postoperatively (40 mg s.c. of enoxaparin, Klexane®, Sanofi, Sweden). Statistics: All data are presented as mean (SE). Areaunder-the-curve calculations were performed using GraphPad Prism 5 (GraphPad software, San Diego, CA). Distributions were analysed using KolmogorovSmirnov testing; differences between groups were calculated with two-tailed unpaired tests using Winstat for Excel® (Kalmia, NY, USA); differences with a p value <0.05 were considered significant.
Results
In the study, 100 patients were initially included after informed consent. All operations were completed laparoscopically. There were no complications, and patients were discharged home on the first (n = 93) or the second (n = 7) postoperative day. No patient was readmitted. In the drop out analysis, incomplete data were found for 1 or 2 patients in each group, so the final analyses were made on 95 patients (Table 1) . Mean operative time was short (30-40 min) and consistent, with no differences between groups (data not shown). The prevalence of risk factors for PONV did not differ between groups (Table 1 ). In addition, there were no statistically significant differences between groups for number of rescue injections per person: 2.0 (0.4) for controls, 1.5 (0.3) for injection-treated and 2.2 (0.4) for orally pretreated patients (Table 1) . A minority of patients were satisfied with our standard antipain medication, 22 % in the control group, 31 % in the orally treated group and 30 % in those pretreated with parenteral betamethasone; the numerical differences did not reach statistical significance. These patients needed no additional pain medication. For the primary endpoint, patients scored nausea to be at its peak between 2 and 8 h after surgery (Fig. 1) . No statistically significant differences were observed, neither between the two groups receiving active betamethasone nor between salinetreated controls and either active group, at any point in time. Total amount of nausea in the time studied is expressed as the area under curve (AUC). No differences could be seen between the groups (Fig. 2) . Nausea was reduced overnight but was still higher at 6 a.m. on the first postoperative morning compared with preoperative values (p < 0.0001).
Betamethasone injection caused a small but statistically significant reduction of tiredness vs. controls at one time point, viz. on arrival to the recovery room (p = 0.0054); oral administration did not (p = 0.2012). After that point in time, there were no other differences between groups receiving active treatment (Fig. 3) .
Discussion
Postoperative nausea and vomiting (PONV) is often a major determinant of time to discharge from hospital. When present, PONV renders postoperative nursing more difficult and impairs patients' rapid return to oral alimentation. Premedication with corticosteroids has been used extensively in PONV prophylaxis. Such medication has been reported to be of value in several different types of surgery. 2, [15] [16] [17] Our previous ERAS protocol included parenterally administered corticosteroids since 10 years and was based on literature studies as well as one study from our own unit 8 The experience with preoperative corticosteroids in bariatric surgery is however limited. 2, 5 Most studies use dexamethasone as the corticosteroid and, importantly, as one part of multimodal treatments. Studies with the steroid as the independent variable are few. Hence, it is difficult to ascertain the value of the steroid per se. Two separate Scandinavian studies have shown betamethasone to have favourable effects in preventing PONV. 6, 7 Thagaard et al. found no significant difference between the effect on PONV in a randomized study comparing dexamethasone and betamethasone. 8 The present study was designed to study the efficacy of our current ERAS protocol and whether it was possible to change to a simpler, oral administration. We therefore examined the possible effects on PONVof a standard dose of betamethasone given orally or parenterally, in a setting of gastric bypass surgery. Non-diabetic patients were chosen since corticosteroids in this dose may affect blood sugar levels after surgery. 5, 18 The design chosen included a positive control as well as a placebo arm. Patients, surgeons and ward personnel were blinded to which treatment had been given. Sample size was determined from a previous pilot study comprising 25 + 25 patients, 10 where there was a small but statistically significant advantage of oral betamethasone over control. Furthermore, we used continuous VAS data for the studied variables to improve statistical analysis and not just the presence or absence of PONV. This technique is based on patients' self-reporting, is well validated 11, 19 and has previously been used in studies on postoperative discomfort [e.g. 8, 20, 21 ]. We found no differences in the effect on nausea, neither for parenteral nor for oral administration over placebo control. This might be due to a power problem of the study, though our samples and dosages were equivalent to what has previously been used in the literature. 6, 8 Also, the power analysis was based on a pilot study from our own practice where the same design was used in a study on postoperative nausea in 50 randomized subjects. 10 Another possibly contributing factor may be that the level of nausea was low also in the placebotreated control group, with a peak average of only around 20 on a 100-mm scale, and few rescue injections had to be given. Our short operating times and modern anaesthetic techniques may, at least in part, explain these low levels of nausea. A correlation has been reported for shorter operating times giving lower levels of nausea. 22 On the other hand, Aasboe et al. 6 found a positive effect of betamethasone in ambulatory surgery patients, with operations lasting only 25-35 min, even shorter times than in the present study. Our findings suggest that also type of surgery and/or non-pharmaceutical measures may be of importance in the prevention of PONV. It is naturally better to use prophylactic measures than to treat the components of PONV. Team experience using modern anaesthetic techniques, keeping operating times short and mobilizing patients rapidly are cornerstones to our protocol. For treatment of PONV, our rescue injection using ondansetron or droperidol were largely successful, as evidenced by the low nausea scores. The single point in time where groups differed was in tiredness on arrival to the recovery room. At that one time point, patients that had received injected betamethasone reported significantly less tiredness than did saline-treated control patients. We used only non-diabetic patients and administered only electrolyte solutions during the time of the study. The observed effect could well be due to a short rise in blood glucose levels, in analogy to what has been previously reported. 5, 18 A limitation of the present study is thus that the results may not be applicable to other departments with other background conditions. But the importance of reevaluating existing ERAS protocols is generalizable. Such updating can be recommended for other departments where surgical and anaesthetic techniques are improving.
The value of corticosteroids, in this study betamethasone, in preventing low-grade PONV seems to be limited or nonexistent. Since betamethasone and dexamethasone have been found to be equally effective, 8 similar results should be expected for dexamethasone. It can be concluded that since modern RYGB surgery in a specialized unit causes such low-grade nausea even in a placebo-treated control group, the need for the inclusion of corticosteroids in an ERAS protocol can be questioned. This is compatible with previous findings that shorter operating times cause less nausea. 22 Our findings underline the importance of continuous monitoring and adjustment of ERAS protocols, to adapt to changes in surgical and anaesthetic techniques.
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